@article{82,
  author = {Krisztián Szigeti and Nikolett Hegedus and Kitti Racz and Ildikó Horváth and Daniel Veres and David Szollosi and Ildiko Futo and Károly Módos and Tamas Bozo and Kinga Karlinger and Noemi Kovacs and Zoltán Varga and Magor Babos and Ferenc Budan and Parasuraman Padmanabhan and Balazs Gulyas and Domokos Máthé},
  title = {Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent},
  abstract = {Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with (201)T1. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II); iron(III); octadecacyanide) doped with (201)T1 isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm(3)) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.},
  year = {2018},
  journal = {CONTRAST MEDIA & MOLECULAR IMAGING},
  pages = {UNSP 2023604},
  issn = {1555-4309},
  doi = {10.1155/2018/2023604},
}